[1]中华医学会.病毒性肝炎防治方案[J].中华传染病杂志, 1995, 13 (4) ∶241-247.
|
[2] DeBleserPJ, NikiT , RogiersV , etal.Transforminggrowthfactor-be tageneexpressioninnormalandfibroticratliver[J].JHepatol, 1997, 26 (4) ∶886-93.
|
[3]刘芳, 刘金星, 李兵顺, 等.转化生长因子β1在慢性乙型肝炎患者肝细胞损伤和肝纤维化形成中的作用[J].中华传染病杂志, 1999, 19 (4) ∶241-244.
|
[4]叶维法, 钟振义.肝炎学大典[M].天津:天津科学技术出版社.1996∶344.
|
[5]毕爱华.医学免疫学[M].北京:人民军医出版社.1995∶78.
|
[6] ItoN , Kawatas, TsushimaH , etal.Increasedcirculatingtransforminggrowthfactorbeta1inapatientwithgianthepatichemangioma:possiblecontributiontoanimpairedimmunefunction[J].Hepatology, 1997, 25 (1) ∶93-6.
|
[7]刘丽霞, 张铮, 苏先狮, 等.慢性活动性乙型肝炎患者细胞免疫功能检测及临床意义[J].中国免疫学杂志, 1995, 11 (3) ∶176-178.
|
[8]陈慰峰, 金伯泉.医学免疫学[M].第3版.北京:人民卫生出版社, 2001∶92.
|
[1] | Ziyi LI, Wanjie ZHANG, Fuchun WANG, Xiaorong MAO, Junfeng LI. Role of T lymphocytes in primary sclerosing cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2926-2931. doi: 10.3969/j.issn.1001-5256.2023.12.026 |
[2] | Long LIU, Ke SHI, Qun ZHANG, Chongping RAN, Jie HOU, Yi ZHANG, Xianbo WANG. Risk factors for hepatocellular carcinoma in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(7): 1589-1593. doi: 10.3969/j.issn.1001-5256.2021.07.022 |
[3] | Yuecheng YU, Chengwei CHEN. Pathogenesis of drug-induced liver injury: Current understanding and future needs[J]. Journal of Clinical Hepatology, 2021, 37(11): 2515-2524. doi: 10.3969/j.issn.1001-5256.2021.11.003 |
[4] | Qu Yao, Zhang Wei. Role of cell apoptosis in the pathogenesis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1397-1400. doi: 10.3969/j.issn.1001-5256.2019.06.049 |
[5] | Chang BinXia, Wang Hua, Zou ZhengSheng, Li BaoSen, Gao Bin. Pathogenesis and novel therapeutic targets of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2014, 30(2): 113-117. doi: 10.3969/j.issn.1001-5256.2014.02.004 |
[6] | Liu HongHong, Fu JunLiang, Fu BaoYun, Zhang Zheng, Xu RuoNan, Luo ShengQiang, Shi Ming, Li YongGang, Wang FuSheng. The pathogenesis and risk factors related to prognosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(2): 153-155. |
[7] | Luo FangQiong, Pan Yu, Liu JingJing, Zhang Peng, Niu JunQi, Jiang YanFang. The Impact of Adefovior dipivoxil on Th1/Th2 cytokines in chronic hepatitis B Patients[J]. Journal of Clinical Hepatology, 2010, 26(1): 19-21. |
[8] | Huang ZhongFa, Zhu Qing, Fu QiMei, Bu QuanHui, Shi BinBin. The effect of Interferon treatment on cellular immuneresponses in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2009, 25(5): 326-328. |
[9] | Zhao Shuang, Yan XueBing, Wang JinZhang, Hao JunGui, Wang MingShan, Feng Xia, Wan MeiRong. The study on imblance of cytotoxic T cells subtype (Tc1/Tc2) in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(6): 417-419. |
[17] | Yin HongZhu, Liu JinXing, Cao ZhiChen, Li BingShun, Tang HuiHua, Feng ZhongJun. The Study of the role of Soluble Intercellular Adhesion Molecule-1 in Patients with Chronic hepatitis B[J]. Journal of Clinical Hepatology, 2000, 16(4): 230-231. |